Clinical trials: Advanced Renal Cell Carcinoma
Kidney Cancer
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00072046
- Testing
- bevacizumab, recombinant interferon alfa
- Where
- 493 sites in United States, Canada
- Volunteers
- 732 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Renal Cell
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).
- Trial name
- NCT04033991
- Testing
- Sunitinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 684 people
- Sponsor
- Pfizer
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Advanced Cancer, Gastric Adenocarcinoma
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer.
- Conditions
- Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer
- Trial name
- NCT02082210
- Testing
- Emibetuzumab, Ramucirumab
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Renal Cell Carcinoma, Renal Cancer
Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer
This is a multicenter, exploratory, prospective study to identify angiogenesis and immune-related biomarkers predictive of progression free survival in patients with metastatic or advanced renal cell carcinoma treated by a…
- Conditions
- Renal Cell Carcinoma, Renal Cancer, Renal Cancer Metastatic
- Trial name
- ANGIOCOR (NCT05285579)
- Testing
- Blood collection, Tumour samples
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Renal Cell Carcinoma
Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
Combined sunitinib and bevacizumab in advanced renal cell carcinoma.
- Trial name
- NCT02919371
- Testing
- Sunitinib, Bevacizumab
- Where
- Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Renal Cell Carcinoma
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma
This study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer
- Trial name
- NCT00417677
- Testing
- Combination of Temsirolimus and Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 124 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Soft Tissue Sarcoma, Renal Cell Carcinoma
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study.
- Conditions
- Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma
- Trial name
- NCT05229601
- Testing
- HFB301001
- Where
- 10 sites in United States, Spain
- Volunteers
- 31 people
- Sponsor
- HiFiBiO Therapeutics
Carcinoma, Renal Cell
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one…
- Trial name
- NCT00338884
- Testing
- Sunitinib malate
- Where
- 15 sites in Argentina, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Adenocarcinoma of the Bladder, Distal Urethral Cancer
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent, locally advanced, or metastatic cancer of the urothelium.
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer
- Trial name
- NCT00407485
- Testing
- ziv-aflibercept, pharmacological study
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Endometrial Cancer
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00659568
- Testing
- metformin hydrochloride, temsirolimus
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell, Kidney Neoplasms
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
This is a first in human study of AGS-16M18 given every week to subjects with advanced renal cell cancer. AGS-16M18 will be administered as a 60 minute IV infusion on consecutive days until the disease worsens.
- Conditions
- Carcinoma, Renal Cell, Kidney Neoplasms, Kidney Diseases
- Trial name
- NCT00816686
- Testing
- AGS-16M18
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Astellas Pharma Inc
Kidney Neoplasms
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
- Trial name
- NCT00054886
- Testing
- SU-011,248
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer
Renal Cell Carcinoma, Renal Cancer
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus.
- Trial name
- NCT00827359
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center